Use of drug-eluting stents as a function of predicted benefit: Clinical and economic implications of current practice

Archives of Internal Medicine

Volumn 172, Issue 15, 2012, Pages 1145-1152

  Amin, Amit P ^a   Spertus, John A ^b,c   Cohen, David J ^b,c   Chhatriwalla, Adnan ^b   Kennedy, Kevin F ^b   Vilain, Katherine ^b   Salisbury, Adam C ^b,c   Venkitachalam, Lakshmi ^c   Lai, Sue Min ^d   Mauri, Laura ^e   Normand, Sharon Lise T ^g,h   Rumsfeld, John S ^i,j   Messenger, John C ⁱ   Yeh, Robert W ^f  

^a BARNES JEWISH HOSPITAL   (United States)

^b Saint Luke's Mid America Heart and Vascular Institute   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BARE METAL STENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG ELUTING STENT; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK ASSESSMENT; TARGET VESSEL REVASCULARIZATION; UNITED STATES;

AGED; ANGIOPLASTY, BALLOON, CORONARY; COMPARATIVE EFFECTIVENESS RESEARCH; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84865677064     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.3093     Document Type: Article

References (34)

1. Saia F, Marzocchi A, Serruys PW. Drug-eluting stents. The third revolution in percutaneous coronary intervention. Ital Heart J. 2005;6(4):289-303.
2. Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198-3206.
3. Gualano SK, Gurm HS, Share D, et al. Temporal trends in the use of drug-eluting stents for approved and off-label indications: a longitudinal analysis of a large multicenter percutaneous coronary intervention registry. Clin Cardiol. 2010;33(2):111-116.
4. Krone RJ, Rao SV, Dai D, et al ACC/NCDR Investigators. Acceptance, panic, and partial recovery the pattern of usage of drug-eluting stents after introduction in the U.S. (a report from the American College of Cardiology/National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2010;3(9):902-910.
5. Lopez JJ, Keyes MJ, Nathan S, et al. Rapid adoption of drug-eluting stents: clinical practices and outcomes from the early drug-eluting stent era. Am Heart J. 2010;160(4):767-774.
6. Yeh RW, Chandra M, McCulloch CE, Go AS. Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Med. 2011;9:78.
7. Stone GW, Parise H, Witzenbichler B, et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2010;56(19):1597-1604.
8. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357(14):1393-1402. (Pubitemid 47541971)
9. Varani E, Guastaroba P, Di Tanna GL, et al. Long-term clinical outcomes and costeffectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation. EuroIntervention. 2010;5(8):953-961.
10. Bertrand OF, Faurie B, Larose E, et al. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents. J Invasive Cardiol. 2008;20(3):99-104. (Pubitemid 351346280)
11. Schapiro-Dufour E, Cucherat M, Velzenberger E, Galmiche H, Denis C, Machecourt J. Drug-eluting stents in patients at high risk of restenosis: assessment for France. Int J Technol Assess Health Care. 2011;27(2):108-117.
12. Ryan J, Cohen DJ. Are drug-eluting stents cost-effective? It depends on whom you ask. Circulation. 2006;114(16):1736-1744.
13. Vaitkus PT. Common sense, dollars and cents, and drug-eluting stents. J Am Coll Cardiol. 2006;48(2):268-269.
14. Groeneveld PW, Suh JJ, Matta MA. The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review. J Interv Cardiol . 2007;20(1):1-9. (Pubitemid 46161058)
15. Chew DP. Cost-effectiveness of drug-eluting stents: if only all things were equal. Med J Aust. 2005;182(8):376-377.
16. Eisenberg MJ. Drug-eluting stents: the price is not right. Circulation. 2006;114(16):1745-1754. (Pubitemid 44607124)
17. Groeneveld PW, Polsky D, Yang F, Yang L, Epstein AJ. The impact of new cardiovascular device technology on health care costs. Arch Intern Med. 2011;171(14):1289-1291.
18. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519-1521. (Pubitemid 39410418)
19. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584-2591.
20. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803-2809. (Pubitemid 44305292)
21. Shuchman M. Debating the risks of drug-eluting stents. N Engl J Med. 2007;356(4):325-328. (Pubitemid 46148773)
22. National Cardiovascular Data Registry. CathPCI Registry. http://www.ncdr.com/WebNCDR/elements.aspx. Accessed December 15, 2011.
23. Yeh RW, Normand SL, Wolf RE, et al. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation. 2011;124(14):1557-1564.
24. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706. (Pubitemid 38405384)
25. Yelland LN, Salter AB, Ryan P. Performance of the modified Poisson regression approach for estimating relative risks from clustered prospective data. Am J Epidemiol. 2011;174(8):984-992.
26. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies with correlated binary data [published online November 8, 2011]. Stat Methods Med Res. 2011.
27. Popma JJ, Weiner B, Cowley MJ, Simonton C, McCormick D, Feldman T. FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations. J Interv Cardiol. 2007;20(6):425-446. (Pubitemid 350179473)
28. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of firstgeneration drug-eluting stents: a cause for concern. Circulation. 2007;115(11):1440-1455. (Pubitemid 46648381)
29. Roger VL, Go AS, Lloyd-Jones DM, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics- 2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
30. Anderson JL, Adams CD, Antman EM, et al American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of PatientsWith Unstable Angina/Non- STElevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50(7):e1-e157.
31. Anderson JL, Adams CD, Antman EM, et al; 2011 Writing Group Members; ACCF/AHA Task Force Members. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123(18):e426-e579.
32. Venkitachalam L, Lei Y, Stolker JM, et al EVENT Registry Investigators. Clinical and economic outcomes of liberal versus selective drug-eluting stent use: insights from temporal analysis of the multicenter Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. Circulation. 2011;124(9):1028-1037.
33. Department of Health Care Policy, Harvard Medical School. MassDAC Online Risk Calculators. http://www.massdac.org/riskcalc-revasc. Accessed December 15, 2011.
34. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160(6):1035-1041.